Design Therapeutics (DSGN) Total Non-Current Liabilities (2020 - 2021)
Design Therapeutics' (DSGN) quarterly Total Non-Current Liabilities came in at $8.8 million in Q3 2021, up 157.8% quarter-over-quarter from $3.4 million in Q2 2021.
Design Therapeutics (DSGN) Total Non-Current Liabilities (2020 - 2021) Analysis & Trends
Design Therapeutics has disclosed Total Non-Current Liabilities across 2 years of filings, most recently posting $8.8 million for Q3 2021.
- Total Non-Current Liabilities for Q3 2021 came in at $8.8 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2021 was $8.8 million (changed N/A YoY), and the FY2020 annual result was $2.3 million, changed N/A from the prior year.
- Total Non-Current Liabilities came in at $8.8 million for Q3 2021 at Design Therapeutics, up from $3.4 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $8.8 million in Q3 2021 to a low of $2.3 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Design Therapeutics | 763.94 Mn | 541.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 8.78 Mn |
| Jun 30, 2021 | 3.41 Mn |
| Mar 31, 2021 | 3.71 Mn |
| Dec 31, 2020 | 2.33 Mn |